ArticleCureus2026
Primary Synovial Sarcoma of the Prostate: A Case Report and Review of the Literature.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary synovial sarcoma of the prostate is exceptionally rare. Its nonspecific presentation and often normal or low prostate-specific antigen (PSA) levels may delay diagnosis. A 49-year-old man presented with lower urinary tract symptoms and gross hematuria. Digital rectal examination revealed a markedly enlarged, firm, irregular prostate. The serum PSA level was 0.34 ng/mL. Pelvic magnetic resonance imaging showed a 9.4 × 7.4 × 6.5 cm heterogeneous prostatic mass with loss of the rectoprostatic fat plane, without definitive evidence of metastatic disease on staging. Transrectal ultrasound-guided biopsy demonstrated a monophasic spindle-cell neoplasm with immunohistochemical findings consistent with synovial sarcoma. Robot-assisted radical prostatectomy was converted to an open approach to facilitate resection. Tumor was identified in tissue from the rectoprostatic margin, while the overall margin status was indeterminate because of tumor fragmentation, raising concern for microscopic residual disease. The patient received adjuvant pelvic radiotherapy followed by doxorubicin and ifosfamide chemotherapy. At 20 months, he remained alive without radiologic evidence of recurrence or metastasis. Primary prostatic synovial sarcoma should be considered in younger to middle-aged patients with obstructive urinary symptoms, a large prostatic mass, and a normal or low PSA level. Diagnosis relies on histopathologic assessment, supported by immunohistochemistry and molecular testing whenever available. Management should be individualized through multidisciplinary discussion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.